Rutvikkumar Jadvani

Rhabdomyolysis is a clinical syndrome characterized by the breakdown of skeletal muscle, leading to the release of creatine kinase (CK), myoglobin and electrolytes into the circulation. This can result in acute kidney injury and other complications. Common etiologies include trauma, medications and metabolic disorders. We report a case of semaglutide-associated rhabdomyolysis in a 36-year-old obese male who presented with bilateral lower extremity pain, cramping and dark urine 6 days after increasing his weekly dose from 1.7 mg to 2.4 mg. The dose had been titrated weekly from 0.25 mg to 1.0 mg, then to 1.7 mg, and finally to 2.4 mg. Laboratory evaluation revealed markedly elevated CK (16 202 U/L; normal: 20–200 U/L) and liver enzymes (aspartate aminotransferase: 279 U/L, alanine aminotransferase: 77 U/L), consistent with rhabdomyolysis. After excluding other common causes through clinical assessment and diagnostic workup, this case underscores the importance of recognizing this rare but potentially serious adverse effect of semaglutide.